Effects of romosozumab and teriparatide on hip bone using 3D-SHAPER in postmenopausal women with osteoporosis.

JBMR Plus · 2025 · PMC12526953 · PMID 41104374

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Gains in trabecular vBMD were larger with romosozumab but did not reach statistical significance between the treatment groups. 6 While QCT is very useful in differentiating between the effects of therapies on bone compartments, it is not widely available in clinical practice and involves greater exposure to ionizing radiation than DXA.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.